Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Nov 14:17:5303-5314.
doi: 10.2147/IJN.S379792. eCollection 2022.

Macrophage-Targeted Berberine-Loaded β-Glucan Nanoparticles Enhance the Treatment of Ulcerative Colitis

Yuying Xu #  1 , Jintao Huang #  2 , Yapei Fan  1 , Haiyue Long  1 , Minting Liang  1 , Qunjie Chen  1 , Zhiping Wang  2 , Chaoxi Wu  1 , Yifei Wang  1
Affiliations

Macrophage-Targeted Berberine-Loaded β-Glucan Nanoparticles Enhance the Treatment of Ulcerative Colitis

Yuying Xu et al. Int J Nanomedicine. .

Abstract

Aim: This study focuses on constructing of an anti-inflammatory drug delivery system by encapsulation of berberine in the β-glucan nanoparticles and evaluates its effect on treating ulcerative colitis.

Methods: β-Glucan and the anti-inflammatory drug berberine (BER) are self-assembled into nanoparticles to construct a drug delivery system (GLC/BER). The interaction between the drug and the carrier was characterized by circular dichroism, ultraviolet-visible spectroscopy, and dynamic light scattering. The anti-inflammatory effect of the GLC/BER was evaluated through a lipopolysaccharide (LPS)-induced RAW264.7 macrophage inflammation model and a sodium sulfate (DSS)-induced C57BL/6 mouse ulcerative colitis model.

Results: The GLC/BER nanoparticles have a particle size of 80-120 nm and a high encapsulation efficiency of 37.8±4.21%. In the LPS-induced RAW264.7 macrophage inflammation model, GLC/BER significantly promoted the uptake of BER by RAW264.7 cells. RT-PCR and ELISA assay showed that it could significantly inhibit the inflammatory factors including IL-1β, IL-6 and COX-2. Furthermore, GLC/BER shows inhibiting effect on the secretion of pro-inflammatory factors such as IL-1β and IL-6, down-regulating the production of nitrite oxide; in animal studies, GLC/BER was found to exert a relieving effect on mice colitis.

Conclusion: The study found that GLC/BER has an anti-inflammatory effect in vitro and in vivo, and the GLC carrier improves the potency and bioavailability of BER, providing a new type of nanomedicine for the treatment of colitis.

Keywords: anti-inflammation; chiral; drug carrier; immunoregulation; β-glucan.

PubMed Disclaimer

Conflict of interest statement

The authors report no conflicts of interest in this work.

Figures

Figure 1
Figure 1
The preparation of GLC/BER and the proposed therapeutic effect on colitis.
Figure 2
Figure 2
Characterizations of GLC and GLC/BER. Photographs of GLC, BER and GLC/BER in solution, Inset: TEM images of the nanoparticles (A); DLS results and particle size distribution of GLC and GLC/BER (B); UV spectrum analysis of BER and GLC/BER (C); CD spectra of BER and GLC/BER (D).
Figure 3
Figure 3
Cumulative release statistics of GLC/BER in vitro under different gastrointestinal conditions (48h).
Figure 4
Figure 4
The uptake of BER (A, C, E and G) and GLC/BER (B, D, F and H) in RAW264.7/Caco-2 cells was determined after incubation for 1h and 4h.
Figure 5
Figure 5
The effects of GLC, BER and GLC/BER on the mRNA expression of COX-2, IL-1β, IL-6 (A) and IL-1β, IL-6 (B) and NO (C) secretion of RAW264.7 macrophages induced by LPS after incubation for 12 hours. Each value represents the mean ±SEM of three separate experiments. Each group was compared with the cell blank control group. **p<0.01, ***p<0.001, ****p<0.0001.
Figure 6
Figure 6
Effects of GLC/BER on alleviating the symptoms of DSS-induced colitis in mice. Experimental protocol of DSS -nduced colitis in mice (A); Body weight change (B); DAI score (C); Statistical analysis of colon length (D); Representative view of colon (E). Data were presented as mean standard deviation (n=6). Each group was compared with the DSS group, *P<0.05, **P<0.01, ****P<0.0001.
Figure 7
Figure 7
H&E staining of colonic sections at 100 and 200 magnification. CTRL (A); DSS (B); DSS+GLC (C); DSS+BER (D); DSS+GLC/BER (E); Colon histopathological injury score (F). Organ tissue sections of control and GLC groups (G), *P<0.05, ***P<0.001.
See this image and copyright information in PMC

References

    1. Li S, Wu B, Fu W, Reddivari L. The anti-inflammatory effects of dietary anthocyanins against ulcerative colitis. Int J Mol Sci. 2019;20(10):2588. doi:10.3390/ijms20102588 - DOI - PMC - PubMed
    1. Hodson R. Inflammatory bowel disease. Nature. 2016;540(7634):S97. doi:10.1038/540S97a - DOI - PubMed
    1. Friedrich MJ. Inflammatory bowel disease goes global. JAMA. 2018;319(7):648. - PubMed
    1. Tsang L, Banerjee N, Tabibian JH. Bloody diarrhea and weight loss in a patient in remission from ulcerative colitis. Gastroenterology. 2019;157(5):1207–1209. doi:10.1053/j.gastro.2019.01.272 - DOI - PubMed
    1. Bitzer ZT, Elias RJ, Vijay-Kumar M, Lambert JD. (-)-Epigallocatechin-3-gallate decreases colonic inflammation and permeability in a mouse model of colitis, but reduces macronutrient digestion and exacerbates weight loss. Mol Nutr Food Res. 2016;60(10):2267–2274. doi:10.1002/mnfr.201501042 - DOI - PubMed